IL2RA and acute myeloid leukemia: In the AML cohort, there were 9 out of 54 (16.7%) cases with high IL2RA expression in CBF AML subgroup, 30 out of 145 (20.3%) cases with high IL2RA expression in intermediate-risk AML and 9 out of 37 (24.3%) cases in poor-risk AML subgroup.